UCB SA (OTCMKTS:UCBJY – Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 11,143 shares, a decline of 73.7% from the September 15th total of 42,361 shares. Based on an average daily volume of 83,317 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.
UCB Price Performance
UCBJY opened at $113.96 on Tuesday. UCB has a 1 year low of $112.15 and a 1 year high of $168.76. The firm has a 50 day moving average price of $122.64 and a 200 day moving average price of $136.53.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the company. Zacks Research lowered UCB from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 16th. Barclays downgraded UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Jefferies Financial Group raised UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.
UCB Company Profile
UCB SA is a Belgium-based biopharmaceutical company that discovers, develops and commercializes medicines for severe diseases, with a primary focus on neurology and immunology. The company serves patients and healthcare professionals in markets around the world through its research, manufacturing and commercial operations.
UCB’s medicines include Bimzelx (bimekizumab), used to treat several inflammatory conditions; Cimzia (certolizumab pegol), an immunology therapy; and Fintepla (fenfluramine), a treatment for certain severe epileptic syndromes.
Further Reading
- Five stocks we like better than UCB
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
